Presentation is loading. Please wait.

Presentation is loading. Please wait.

A proposed algorithm for the handling of glucocorticoid (GC) therapy in patients with active or flaring SLE. Mild: presence of only BILAG C or ≤1 BILAG.

Published byBohuslav Müller Modified over 5 years ago

Similar presentations

Presentation on theme: "A proposed algorithm for the handling of glucocorticoid (GC) therapy in patients with active or flaring SLE. Mild: presence of only BILAG C or ≤1 BILAG."— Presentation transcript:

1 A proposed algorithm for the handling of glucocorticoid (GC) therapy in patients with active or flaring SLE. Mild: presence of only BILAG C or ≤1 BILAG B manifestation or physician global assessment (0–3) ≤1. A proposed algorithm for the handling of glucocorticoid (GC) therapy in patients with active or flaring SLE. Mild: presence of only BILAG C or ≤1 BILAG B manifestation or physician global assessment (0–3) ≤1. Moderate: presence of ≥2 BILAG B manifestations or physician global assessment (0–3) 1–2. Severe: presence of ≥1 BILAG A manifestations or physician global assessment (0–3) ≥2. BILAG, British Isles Lupus Assessment Group; d/c, discontinue; IV-MP, intravenous methylprednisolone. Antonis Fanouriakis, and George Bertsias Lupus Sci Med 2019;6:e000310 ©2019 by Lupus Foundation of America

Download ppt "A proposed algorithm for the handling of glucocorticoid (GC) therapy in patients with active or flaring SLE. Mild: presence of only BILAG C or ≤1 BILAG."

Similar presentations

LUPUS PATIENTS’ NEEDS AND PERSPECTIVES IN SOUTHEASTERN EUROPE: DATA FROM THE CRETAN LUPUS COHORT “LETO” Kabouraki E.1, Rapsomaniki P.1, Terizaki M.1,

LUPUS PATIENTS’ NEEDS AND PERSPECTIVES IN SOUTHEASTERN EUROPE: DATA FROM THE CRETAN LUPUS COHORT “LETO” Kabouraki E.1, Rapsomaniki P.1, Terizaki M.1,
Mapping and UTILIZATION of health care services from patients with newLY DiagnosED systemic lupus erythematosus Rapsomaniki P.1, Terizaki M.1, Kabouraki.

Mapping and UTILIZATION of health care services from patients with newLY DiagnosED systemic lupus erythematosus Rapsomaniki P.1, Terizaki M.1, Kabouraki.
Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.

Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.
Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.
Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 4 Antinuclear antibodies and disease activity in SLE
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation  Nicholas J. Gross, MD,

Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation  Nicholas J. Gross, MD,
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Management of Systematic Lupus Erythematosus

Management of Systematic Lupus Erythematosus
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.
Management of Systemic Lupus Erythematosus

Management of Systemic Lupus Erythematosus
Volume 68, Issue 2, Pages (August 2005)

Volume 68, Issue 2, Pages (August 2005)
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.
(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,

(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,
Maria R. Costanzo et al. JCHF 2016;4:

Maria R. Costanzo et al. JCHF 2016;4:
Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.
Association of B cell TLR4 levels to disease activity.

Association of B cell TLR4 levels to disease activity.

Similar presentations

Ads by Google